| Cell line name |
BID019 |
|---|
| Synonyms |
Beth Israel Deaconess 019 |
|---|
| Accession |
CVCL_E6DY |
|---|
| Resource Identification Initiative |
To cite this cell line use: BID019 (RRID:CVCL_E6DY) |
|---|
| Comments |
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771_His772insHis; Zygosity=Unspecified (PubMed=31467113).
|
|---|
| Disease |
Lung adenocarcinoma (NCIt: C3512) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita ...Show all 18 authors... , Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel Botelho Costa, Susumu S. Kobayashi; Show fewer authors
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019) |
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2025 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 1 |
|---|
